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Background: Risperidone long-acting injection (RLAI) has been shown to be efficacious, 
improve compliance, and increase long-term retention rate on therapy. The aim of this work 
was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with 
schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment 
Adherence Registry in Latin America.
Methods: Data were collected at baseline, retrospectively for the 12 months prior to baseline, 
and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed 
by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global 
Impression of Illness Severity (CGI-S), Personal and Social Performance (PSP), and Global 
Assessment of Functioning (GAF) scores. Relapse and treatment were also registered.
Results: Patients were recruited in Mexico (n = 53), Brazil (n = 11), and Colombia (n = 15). 
Sixty-five percent (n = 52) were male, and mean age was 32.9 years. Patients were classified 
as having schizophrenia (n = 73) or schizoaffective disorder (n = 6). The mean dose of RLAI 
at six months was 34.1 mg (standard deviation = 10.2 mg). The percentage of hospitalized 
patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P , 0.001). 
Significant changes were registered on CGI-S, GAF, and PSP scores.
Conclusions: RLAI was associated with an improvement in clinical symptoms and functioning, 
and a greater reduction in hospitalization.
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Introduction
Pharmacological treatment with antipsychotics is the essential component of schizophrenia 
therapy. The development of atypical antipsychotics has proven to be an important advance 
in the control of this disease. These medications show high levels of efficacy in control-
ling positive and negative symptoms,1,2 a modest effect on cognitive function,3,4 and a 
positive effect on affective symptoms.5,6 In addition, the atypical antipsychotics have been 
associated with an improvement in quality of life and performance in social contexts.7,8 
Furthermore, it is well established that the prescription of atypical antipsychotics is associ-
ated with a decrease in the incidence of extrapyramidal symptoms.9
Despite the obvious benefits, it is well known that an significant proportion of 
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of schizophrenic patients follow their treatment, another 
one-third present partial adherence to treatment, and the 
final one-third fail to follow treatment regimens.11,12 More 
than 35% of patients who start treatment have problems 
following their treatment protocol during the first six weeks, 
and the nonadherence rate has been reported to increase up 
to 75% after two-year follow-up.13,14 A low adherence rate 
was found after 12 months of treatment for oral therapies, 
including those with atypical antipsychotics.15
The problem of low adherence is shown in studies of the 
first psychotic episode, where symptom remission has been 
observed in 80% of patients treated with antipsychotics.16,17 
However, 80% of patients diagnosed with their first 
schizophrenic or schizoaffective episode present approxi-
mately two relapses in the first five years of the disease,18 
with symptom remission being less likely after each relapse.19 
In addition, a larger number of relapses have been shown 
to be correlated with poor functioning and a reduction in 
response to treatment.20,21 In addition, these patients and 
their caregivers experience extremely high levels of stress 
associated with relapse and hospitalization. Multiple studies 
have shown that low adherence rates in the treatment of 
schizophrenia are associated with a poor prognosis and more 
substantial decline in physical health.22,23
Apart from its impact on prognosis, lack of adherence 
has an important effect on the economic impact of the 
disease and utilization of health resources. Patients with poor 
adherence have a higher rate of hospitalization and longer 
hospital stays.24,25 It has been calculated that improving treat-
ment adherence in patients with schizophrenia could save 
US$100 million dollars in the cost of medical attention by 
reducing both the number and duration of hospitalizations.26 
Therefore, treatment adherence is the one important variable 
that can be controlled to diminish the cost of schizophrenia 
by reducing relapse rates.
The long-acting injectable antipsychotics have a pro-
longed duration of action and may be a solution to decrease 
the relapse rate because they have been shown to increase 
treatment adherence by 10%–40%.27 Many randomized trials 
have been conducted comparing the relapse rates of oral 
versus long-acting injectable antipsychotics. The findings 
of these studies favored the latter form of antipsychotics.28,29 
Despite these findings, and the recommendations for using 
long-acting injectable antipsychotics for patients showing 
poor adherence to oral antipsychotics (recommended in the 
guidelines of the American Psychiatric Association for the 
handling of schizophrenia, UK National Institute for Health 
and Clinical Excellence, Schizophrenia Patient Outcomes 
Research Teams, and the Texas Medication Algorithm 
Project), physicians are reluctant to change their prescribing 
habits. In general, most of the barriers to the prescription of 
long-acting injectable antipsychotics are related to the lack 
of knowledge among doctors on how to use these forms of 
drugs and the idea that they should only be used in a very 
specific group of people, ie, severely ill patients and those 
who have been shown to have poor adherence.
Currently, there is a form of risperidone long-acting 
injectable (RLAI) that has been shown to increase adherence 
to antipsychotic treatments and improve clinical and 
economic parameters in patients with schizophrenia.30–32 
This is the first atypical antipsychotic with a prolonged 
action, and has been shown to induce fewer extrapyramidal 
symptoms when compared with long-acting injectable first-
generation antipsychotics, and to improve adherence and 
reduce relapse rates.33,34
However, as is the case in some other geographic regions, 
prescribing of long-acting risperidone in Latin America is 
uncommon and predominantly used in severe cases and in 
patients with poor adherence to treatment. For this reason, 
the Electronic Schizophrenia Treatment Adherence (e-Star)35 
has been implemented in Latin America as well as in other 
regions. The objective of this project is to determine the 
outcomes and hospitalization rates before and after treat-
ment with RLAI in a group of patients with schizophrenia or 
schizoaffective disorder in a naturalistic setting. We hypoth-
esized that the switch to RLAI will improve the symptoms 
and functioning, thereby reducing hospitalization rates. In 
this report, we present a preliminary prespecified interim 
analysis of the results from this project after six months of 
follow-up.
Methods and materials
This study was conducted in accordance with the regula-
tions on Good Clinical Practice and the Helsinki Declaration 
of the World Medical Association, Edinburgh, 2000. The 
experimental protocol was approved by the different ethics 
committees of each of the participating institutions. Written 
informed consent was obtained from all patients after the 
procedures were carefully explained to them.
subjects
Subjects were recruited from hospitalization services, 
emergency rooms, and outpatient programs in private and 
public institutions from Mexico, Colombia, and Brazil. 
Eligible patients included males, females who were not 
pregnant or lactating, those aged over 18 years, with a Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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diagnosis of schizophrenia or schizoaffective disorder 
according to Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV) criteria. In addition, all 
subjects experienced either acute or chronic episodes that 
could benefit from treatment with RLAI, according to the 
clinical criteria of the researcher. Finally, all subjects had 
to submit written consent. Patients with bipolar disorder, a 
previous history of intolerance or poor response to risperi-
done that was not associated with poor adherence, women 
who were pregnant or planning to get pregnant during the 
two years of follow-up, or women who did not have a reli-
able contraception method available to them were excluded 
from this study.
Design and procedures
The Electronic Schizophrenia Treatment Adherence Registry 
is an independent international registry that records the usage 
of RLAI. The registry had a one-year retrospective analysis 
in which the usage of medications and the hospitalization 
history of each patient were recorded. At baseline, the 
  demographic characteristics of the diseases and the   reasons 
for the change in antipsychotic drugs were registered. The 
severity of the disease was assessed using the   Clinical 
Global Impression-Schizophrenia scale (CGI-SCH).36 
Social functioning was registered using the Personal and 
Social Performance (PSP) scale, and the Global Assessment 
of Functioning (GAF) scale.37 After baseline registration, 
a two-year, prospective follow-up was conducted with 
  evaluations every three months using the CGI-SCH severity 
scale (CGI-SCH SI) as the estimator of efficacy and the PSP 
and GAF scales to assess functionality. The PSP scale is a tool 
that indicates how well a patient functions. The scale ranges 
from 1–100, where 1–10 represents lack of autonomy and 
91–100 represents excellent functioning. The classifications 
are based on the evaluation of four objective indicators, ie, 
activities that contribute to society (including work and 
study), social and personal relationships, taking care of 
oneself, and disturbing and aggressive behaviors.38 In each 
evaluation, adherence and satisfaction with   treatment, other 
medications being taken, side effects, and hospitalizations 
were recorded. The initial doses of RLAI were   prescribed 
according to the clinical criteria of the investigator and the 
condition of the patients. The doses were adjusted during 
follow-up, according to efficacy and tolerability. Concomi-
tant therapy with anticholinergic agents, antidepressants, 
mood stabilizers, benzodiazepines, antipsychotics, and other 
medications were prescribed at the researcher’s discretion 
according to the patient’s condition.
statistical analysis
Demographic and clinical characteristics were analyzed with 
frequencies and percentages for the categorical variables and 
means and standard deviations (SD) for the continuous vari-
ables. McNemar’s test was used to compare the percentage of 
patients hospitalized during the retrospective evaluation with 
those hospitalized during the prospective phase. This test was 
also utilized to determine the usage of concomitant therapy in 
each of these stages. Paired t-tests were used for the efficacy 
analyses of CGI and the functionality with GAF and PSP.
The sample size for a two-year follow-up was based on 
the minimum numbers required to demonstrate a reduction 
in the mean number of days of hospitalization. It is expected 
that patients in this study will have an average baseline of 
21.6 days, and would show an average of 8.8 (SD = 37.1) 
days at the end of the study. These numbers reflect the results 
observed in previous studies with RLAI. The inclusion of 189 
patients will permit us to demonstrate statistical differences 
with a 90% power.
Results
Patients
Seventy-nine patients were recruited in Mexico (n = 53), 
Colombia (n = 15), and Brazil (n = 11). These patients 
successfully completed the six-month follow-up. There 
was a predominance of men (n = 52, 65.8%), with the mean 
sample age being 32.9 years (SD = 8.8). Most of the sample 
was unemployed (n = 59, 74.7%) at the onset of the study, 
and only four patients had a full-time job (5.1%). Seventy-
three patients were classified as schizophrenic (92.4%), 
and six were classified as having schizoaffective disorder 
(7.6%). The mean length of illness was 8.5 years (SD = 7.0). 
At baseline evaluation, 10 patients were hospitalized. Only 
one patient stopped treatment with RLAI because he was 
lost during follow-up (1.3%).
The most important clinical reasons to start treatment 
with RLAI were a low adherence rate (n = 29, 36.7%) and 
a lack of efficacy (n = 28, 35.4%). A recommendation of a 
maintenance treatment was the third reason to start RLAI 
treatment (n = 12, 15.2%). In addition, five patients decided 
to start RLAI therapy due to its convenience (6.3%).
hospitalization
There was a significant reduction in the need for hospital-
ization services after patients switched to treatment with 
RLAI. The proportion of hospitalized patients significantly 
decreased from 28.2% to 5.1% (P , 0.001), and the duration 
of hospitalization also significantly decreased from 13 days Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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to 2.1 days (P = 0.002) when comparing the six-month 
retrospective evaluation versus the six-month prospective 
evaluation of these variables (Table 1).
clinical outcomes
Compared with the initial phase, the mean CGI-SCH SI 
global score significantly improved after six months of treat-
ment (4.19, SD = 1.01 versus 3.02, SD = 1.3, respectively, 
P , 0.001). At the endpoint, the severity of positive, nega-
tive, depressive, and cognitive symptoms were scored in a 
1–3 range (mild symptoms). In addition, global functioning 
significantly improved after six months of RLAI treatment 
(55.7, SD = 16.9 versus 69.9, SD = 16.1, P , 0.001). Social 
functioning, which was evaluated using the PSP scale, 
also showed a significant improvement when compared 
with the baseline conditions for all the follow-up periods. 
Furthermore, a comparison of PSP scores in outpatients and 
hospitalized patients showed that the latter failed to present 
a significant change (Figure 1).
Patients reported being satisfied (n = 22, 33.8%) or very 
satisfied (n = 39, 60%) with the RLAI treatment, and only one 
patient was unsatisfied with the treatment (1.5%). Sixty-five 
patients (82.2%) received a prescription of 25 mg of RLAI at 
treatment onset whereas two patients were prescribed an initial 
dose of 50 mg. The mean RLAI doses at onset, and at three and 
six months, were 27.5 mg (SD = 5.8), 31.8 mg (SD = 8.7), and 
34.1 mg (SD = 10.2), respectively. At the last time point, 12 
patients were on a 50 mg dose and one patient was receiving 
75 mg. The proportion of patients receiving either 25 mg or 
37.5 mg was similar (n = 25 [46.2%] and n = 29 [37%], respec-
tively). Adherence to treatment at the six-month follow-up was 
excellent (81%–100%) in 65 patients (82.2%). The remaining 
patients were not included in the final evaluation.
Some patients received haloperidol 1–5 mg/day and 
risperidone 2–4 mg/day in addition to RLAI. The prescrip-
tion patterns of antipsychotics prior to treatment and during 
treatment are shown in Table 2.
Concomitant therapy mainly included   antidepressants 
  (fluoxetine, sertraline 20–40 mg/day), mood   stabilizers (val-
proate 200–400 mg/day, carbamazepine 200–400 mg/day, lam-
otrigine 25–100 mg/day), and benzodiazepines (clonazepam, 
lorazepam 2–4 mg/day). Patients were less likely to receive 
concomitant therapy during the study. As a result, there was 
a significant reduction in the prescription of benzodiazepines 
(n = 28, 42% at baseline versus n = 18, 27.3% at the six-month 
follow-up, P = 0.04). Although changes in the prescription 
of drugs other than benzodiazepines were not statistically 
significant, they were also reduced during the RLAI study 
(Figure 2).
Treatment with RLAI was well tolerated during the study. 
Only 16 patients (20.2%) presented side effects, which were 
not serious. The most common side effect was akinesia 
(n = 4, 5%). In addition, three patients showed gastrointes-
tinal disturbances (3.8%) and two patients showed changes 
in metabolism (2.5%). Additionally, two patients (2.5%) 
showed exacerbation of psychosis symptoms and required 
hospitalization.
Discussion
The preliminary results of this multicenter, naturalistic, 
retrospective, and prospective study in Latin America con-
firmed that RLAI improves symptoms and functionality in 
schizophrenic patients, while decreasing the number and 
Table 1 Patients fully hospitalized at least once per period and 
length of stay by period (n = 78)
Patients fully hospitalized1
Period r P P value*
3 months 17 (21.8) 1 (1.3) ,0.001
6 months 22 (28.2) 4 (5.1) ,0.001
Total length of stay (days)2
r P P – r P value**
3 months 7.6 0.4 -7.2 ,0.001
0 (18.3) 0 (3.2) 0 (17.2)
6 months 13 2.1 -11 0.002
0 (30) 0 (10.9) 0 (30.9)
Notes: 1Values shown are the number of patients (%); 2Values shown are the mean 
(median, sD); *P value associated with the hypothesis of no difference between 
retrospective and prospective periods (McNemar’s test); **P values for difference 
P – r calculated using paired t-test. 
Abbreviations: r, retrospective; P, prospective; sD, standard deviation.
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Figure 1 evolution of PsP scores over time.
Notes:  Only  patients  with  a  PsP  score  at  both  baseline  and  six  months  are 
included in this table. *P-value associated with the hypothesis of no difference from 
baseline (paired t-test). change from baseline [mean (sD)]: All patients: baseline vs 
three months 15 (15.5) P , 0.001 and baseline vs six months 16.3 (17,2) P , 0.001; 
Outpatients: baseline vs three months 14.7 (15.1) P , 0.001 and baseline vs six months 
15.9 (16.9) P , 0.001; inpatients: baseline vs three months 18.5 (22), n.s. and baseline 
vs six months 20.7 (21.1), n.s.
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Table 2 Antipsychotics taken, by class, with each class counted only once (n = 79)
Antipsychotic class Retrospective period Baseline  
n (%)
Prospective period
-12 months  
n (%)
-9 months  
n (%)
-6 months  
n (%)
-3 months  
n (%)
3 months  
n (%)
6 months   
n (%)
OA: Any 24 (30.4) 25 (31.6) 29 (36.7) 28 (35.4) 36 (45.6) 8 (10.1) 7 (8.9)
risperidone 12 (15.2) 13 (16.5) 12 (15.2) 14 (17.7) 29 (36.7) 4 (5.1) 4 (5.1)
Olanzapine 6 (7.6) 6 (7.6) 7 (8.9) 6 (7.6) 2 (2.5) 0 (0) 0 (0)
Oc 15 (19) 17 (21.5) 19 (24.1) 18 (22.8) 14 (17.7) 4 (5.1) 3 (3.8)
Dc 9 (11.4) 10 (12.7) 9 (11.4) 10 (12.7) 2 (2.5) 0 (0) 0 (0)
rLAi 0 (0) 0 (0) 0 (0) 0 (0) 79 (100) 79 (100) 78 (98.7)
Note: each patient can appear more than once per time point.
Abbreviations: OA, oral atypical; Oc, oral conventional; Dc, depot conventional; rLAi, risperidone long-acting injectable.
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Figure 2 concomitant therapy. 
Notes: each patient can have more than one medication per timepoint. *P-value associated with the hypothesis of no change from baseline to six months (McNemar test 
on the patients with an evaluation at both visits).
length of hospitalizations. In addition, it shows excellent 
treatment adherence in patients with schizophrenia.
By improving treatment adherence with RLAI, relapses 
and hospitalizations were significantly reduced. Sixty-seven 
patients, representing 84% of our sample, showed no relapse 
or rehospitalization during the first six months of treatment.
This study’s favorable findings with respect to the effi-
cacy of RLAI confirmed the results from previous short- and 
long-term studies that examined the efficacy of RLAI in 
patients with schizophrenia.39–41 The findings of this study 
suggested that there was an improvement in the patients’ 
outcomes when they were switched to the long-term treat-
ment. This was similar to previous studies where treatments 
with other oral or long-acting injectable antipsychotics,42–45 
including patients treated previously with oral risperidone,46 
were switched to RLAI. It is highly likely that this improve-
ment was due to the improvement of partial adherence, as 
shown by the excellent rates of complete adherence found 
in the patients at the end of the study. One of the biggest 
advantages of long-acting injectable antipsychotics is that 
they allow for strict monitoring. Thus, when the patient does 
not inject the medicine, immediate decisions can be made to 
prevent this failure in adherence and to involve the family 
and primary caregivers.47 This is particularly important in 
Latin American countries, where patients frequently have 
poor access to mental health services due to lack of available 
services in all the communities and long distances to mental 
health facilities.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Risk factors for lack of adherence can be conceptualized 
as being related to the patient, the treatment, or the environ-
ment.48 Treatment-related factors are usually lack of efficacy 
and the occurrence of side effects that lead to the patient decid-
ing to suspend their medication. Although the presence of side 
effects is not usually considered a factor directly associated 
with adherence,49 it does influence the patient’s perception of 
the benefits of taking the medication.50 This important factor is 
explained in the model of health beliefs, which proposes that 
patients will value and compare the perceived benefits and 
costs of the medication. If they believe that the benefits out-
weigh the costs, they will generally show a higher adherence 
to treatment.51 Relatively few patients have withdrawn from 
RLAI studies due to side effects (1.2%–16%), and the drug 
is generally well tolerated.52 The results of this study confirm 
that RLAI is a safe and well tolerated treatment option. In 
addition, these findings do not support the perception by some 
doctors and patients that long-acting injectable antipsychotics 
have more side effects than the oral formulations. Indeed, it 
is this inaccurate perception that has limited the prescribing 
of this presentation of antipsychotics.53
The treatment benefits that have been perceived by patients 
include an improvement in general well being, mental health, 
and functionality.54 These benefits for the patient are usually 
not analyzed in controlled clinical studies because these studies 
are designed to focus on establishing efficacy and tolerance. 
Studies focused on the real world, such as this one, allow for 
the assessment of these variables. In our study, we were able 
to show an improvement in patient functionality from the onset 
of the treatment with RLAI. This finding was consistent with 
results found from post hoc analyses of controlled studies55,56 
and studies done in real-world settings,35 which have shown 
an improvement in functionality with RLAI.
The cost of schizophrenia increases four-fold in patients 
who present one relapse,57 and 79% of the direct cost of 
schizophrenia is related to hospitalization or institutional 
care. Interestingly, the medications represent only a small 
fraction (1%–6%) of the overall cost of the disease.58 In this 
study, the preliminary results showed an important reduction 
in the rate of hospitalizations and concomitant therapy, which 
resulted in a lower utilization of resources, which could lead 
to a reduction in the cost of schizophrenia. However, a phar-
macoeconomic study is necessary to determine the possible 
relationship between these variables and a decrease in the 
cost of schizophrenia in Latin America.
It is important to highlight that the patients were pre-
scribed RLAI according to the clinical discretion of the 
researcher. The two main reasons for switching treatments 
were poor adherence and lack of efficacy. Only a small 
number of patients decided to switch to RLAI due to con-
venience. This finding supports the existence of a strong 
misconception in Latin America that long-acting injectable 
antipsychotics should only be used in patients with severe 
symptoms and poor adherence. A recent study examining 
the criteria used for the prescription of long-acting injectable 
antipsychotics found that patients taking depot antipsychotics 
had higher rates of adherence problems and more extrapy-
ramidal symptoms. It is notable that patients who received 
RLAI tended to have more severe disease than those treated 
with long-acting injectable first-generation antipsychotics.59 
The fact that RLAI tends to be prescribed for severe patients 
is likely associated with the perception of a higher efficacy, 
but it supports the hypothesis that there are specific criteria 
being used for its prescription. Studies have shown that 
RLAI was effective and well tolerated in patients in their 
first psychotic episode, reduced hospitalization rates, and 
improved prognosis by reducing relapse.60–62 However, the 
preconceived notions about its use still remain. Other factors 
that have limited the use of long-acting injectable antipsy-
chotics are lack of reimbursement in some settings, and the 
lack of knowledge by doctors, as well as their belief that the 
patient or their family would refuse this form of treatment.63 
However, surveys of outpatients treated with long-acting 
injectable typical antipsychotics have shown that 87% chose 
to continue with this form of the drug.64 The high satisfaction 
rates observed for RLAI in this study suggest that the first 
barrier to its prescription is simply a lack of knowledge.
The main limitations of our study were the lack of a 
control group and that it was not blinded, which allowed for 
possible observational bias. Despite these limitations, it is 
important to establish the relevance of the use of prospective 
data and that it is necessary to use studies focused on the real 
world to evaluate adherence because controlled studies, by 
design, will exclude patients that do not adhere to treatment. 
In addition, the use of the same patient as a control itself 
allowed us to avoid another selection bias.
In summary, our preliminary results highlight the 
efficacy and tolerability of RLAI in schizophrenic patients. 
This treatment reduces the burden on health resources and 
prevents relapses by increasing adherence to treatment. 
Further studies of RLAI in recently diagnosed patients are 
necessary. Given that doctors tend to prescribe long-acting 
injectable antipsychotics only to severe patients and those 
who have shown adherence problems, it is imperative that 
doctors gain a better understanding of long-acting injectable 
antipsychotics.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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